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Abstract
Background: Solvent abuse is a particularly serious issue affecting Aboriginal people. Here we examine the association 
between solvent use and socio-demographic variables, drug-related risk factors, and pathogen prevalence in 
Aboriginal injection drug users (IDU) in Manitoba, Canada.
Methods: Data originated from a cross-sectional survey of IDU from December 2003 to September 2004. Associations 
between solvent use and variables of interest were assessed by multiple logistic regression.
Results: A total of 266 Aboriginal IDU were included in the analysis of which 44 self-reported recent solvent use. 
Hepatitis C infection was 81% in solvent-users, compared to 55% in those reporting no solvent use. In multivariable 
models, solvent-users were younger and more likely to be infected with hepatitis C (AOR: 3.5; 95%CI: 1.3,14.7), to have 
shared needles in the last six months (AOR: 2.6; 95%CI:1.0,6.8), and to have injected talwin & Ritalin (AOR: 10.0; 95%CI: 
3.8,26.3).
Interpretation: High hepatitis C prevalence, even after controlling for risky injection practices, suggests that solvent 
users may form closed networks of higher risk even amongst an already high-risk IDU population. Understanding the 
social-epidemiological context of initiation and maintenance of solvent use is necessary to address the inherent 
inequalities encountered by this subpopulation of substance users, and may inform prevention strategies for other 
marginalized populations.
Background
In developed countries, sexually transmitted infections
(STI) and bloodborne pathogens (BBP) disproportion-
ately affect marginalized populations. In the United
States, Australia, and Canada the combined impact of
poverty, lack of access, and historical and systemic
oppression have resulted in overrepresentation of indige-
nous populations in national HIV/AIDS and STI statis-
tics, especially amongst females and youth[1-6]. Within
Canada, injection drug users (IDU) account for a signifi-
cant proportion of prevalent HIV and other BBP (such as
hepatitis C [HCV]) infections, and are an especially
important risk group sustaining endemicity of these
pathogens within Aboriginal populations[4,7-9]. How-
ever, despite progress in, and substantial efforts towards
both understanding, and addressing BBP epidemics in
Canadian Aboriginal populations[7], the transmission of
some BBP , such as HIV and HCV, appear to be growing
unabated[10-12]. This paradox has motivated researchers
to examine heterogeneity in marginalized subpopula-
tions, with the intention of finding and describing sub-
populations that may be at particularly high risk of BBP
transmission, as well as the environmental contexts
within which they are embedded[13-16].
To this end, solvent abuse has been shown to be a par-
ticularly serious and destructive issue affecting Aborigi-
nal populations in Canada, and elsewhere[17-25]. In
North America, the lifetime use of solvents has been
reported to be as high as 44% in some high-risk
groups[26], with some studies finding the prevalence of
lifetime use at 17% by the eighth grade[27]. Solvent use is
a term broadly applied to the self-administered inhalation
of a variety of volatile, psychoactive substances that are
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found in many common products, including gasoline and
adhesive glue[24,28]. Solvent users have elevated rates of
negative health outcomes including mental illness[29,30],
damage to the central nervous system, heart and lungs
[28,31,32], as well as mortality[32,33]. Contributing to its
perniciousness, solvents are primarily legal and easily
obtainable[18,34]. As well, multiple factors have been
identified as being associated with solvent use, including
age, sex, ethnicity, education level, co-existing alcohol or
other substance use disorders, and child and physical
abuse[35-39]. In youth, solvent use has been linked to
broader societal issues such as higher school drop-out
rates[40], delinquency (including criminal activity)[36,39]
and family conflict[39,41]. Salient to this study, an associ-
ation between chronic solvent use in adolescence and
injection drug use among the most marginalized of popu-
lations has been demonstrated[20,42-44].
On the treatment side, a particular defining feature of
chronic solvent use is that it is typically associated with
the most marginalized populations, with, for example
higher levels of anti-social behaviour, trauma-exposure
and psychiatric morbidities[19,24,45]. In response to the
burgeoning need for Aboriginal-specific programs, Can-
ada has over a dozen solvent abuse treatment centres
spread across the country[46]. These centres operate
under a continuum of interventions, including preven-
tion, early intervention, residential treatment and envi-
ronmental deterrence. Furthermore, evidence suggests
IDU with a solvent use background have a "specific
course of addiction"[39], often with much more detri-
mental outcomes, and a particular intransigency to treat-
ment[39,47]. This "deviant group within a deviant group"
has been recognized since the late 1970s[47], but is still
poorly understood, relative to other IDU groups.
Despite the link observed between solvent use and IDU,
and the disproportionate burden of both solvent abuse
and STI/BBP infection in Aboriginal populations, there is
little published research on solvent use among Aboriginal
IDU. We therefore undertook this study to examine the
association between solvent use and socio-demographic
and drug-related risk factors in Aboriginal IDUs in Mani-
toba, Canada. We were also interested in examining the
relationship between solvent use and injection of other
types of illicit substances, as well as being infected with a
BBP (i.e., HIV and HCV).
Methods
Study setting and survey instrument
The study setting and survey instrument have been
described previously[48-50]. This was a cross-sectional
survey of IDU in Winnipeg, Manitoba, Canada (pop.
675,000) conducted from December 2003 to September
2004. Recruitment was advertised at local community
health centres, meeting places (as identified by key infor-
mants) and word-of-mouth. Eligibility criteria included
self-reported use of illicit injection drugs in the 6-month
period prior to interview and having an age of 15 years or
more. Potential participants made telephone contact with
the study nurse, who administered all surveys in-person.
Interviews took place in a private setting of the partici-
pant's choosing. An honorarium was provided to all study
participants providing written or oral consent. The ques-
tionnaire was divided into three sections. The first sec-
tion consisted of questions based on the respondent's
own characteristics, the second elicited information on
the respondent's egocentric network (i.e., the people with
whom the respondent had regular contact with), while
the third section asked questions on the respondent's
IDU risk network. The first section was of primary inter-
est for this study. The study design was approved by the
Health Research Ethics Board of the University of Mani-
toba and the Winnipeg Regional Health Authority
Research Review Committee.
Measures
The outcome measure in this study was a binary variable
describing solvent use, which was derived from a positive
answer for "Gasoline/Solvents" to the survey item "In the
last 6 months, which of the following drugs have you used
without injecting?" The study sample of IDUs was subset-
ted to only individuals who self-identified as Aboriginal,
and included those who identified as 'First Nations' or
'Metis'. Variables were grouped into four categories:
socio-demographic, injection-related behaviours, other
drug use and BBP status. Socio-demographic variables
included: age, which was categorized as 15-29, 30-39, and
40 years or more; education, which was coded as
'dropped out less than grade 12' or 'grade 12 or higher';
and place of birth, which was coded as 'born inside Mani-
toba' or 'born elsewhere'. Injection-related behaviours
included: locales where drugs were injected (in the last 6
months), and this list included their own house, a family
members' or friends' residences, an empty house, a shel-
ter/hostel, hotel, shooting gallery and on the street; shar-
ing needles (ever and in the last 6 months); sharing other
injection equipment; injecting someone as a service;
injecting someone as a favour; and ease of obtaining nee-
dles. The time frame for the last four questions was 6
months.
Participants were asked which drugs they injected most
frequently and finally, in terms of BBP infection, HIV and
HCV status was assessed using venous blood samples,
tested at Cadham Provincial Laboratory (Winnipeg, MB).
Specimens were screened for HCV and HIV with AxSYM
HCV (Abbott, Mississauga, ON) and AxSYM HIV1/2 gO
(Abbott, Mississagua, ON), respectively. Presumptive
positives were confirmed for HCV with Chiron HCV 3.0
RIBA (Ortho-Clinical Diagnostics, Markham, ON). Pre-Shaw et al. Harm Reduction Journal 2010, 7:16
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sumptive HIV positive specimens were confirmed by
western blot (BioRad, Montreal, QC).
Statistical methods
Associations between solvent use and variables of interest
were assessed using χ2 tests. Variables that were signifi-
cant at the p < .20 level were included in multivariable
logistic regression analysis. A parsimonious model was
desired, so therefore, with the exception of sex (which
was forced into the model to adjust for its effects), a back-
wards stepwise regression procedure was used to elimi-
nate variables that were not significant at the p < .05 level.
Odds ratios (OR) and their 95% confidence intervals (95%
CI) are reported for univariate and multivariable analy-
ses. Multicollinearity of the final model was assessed
using VIF and tolerance statistics. Stata version 9 was
used in performing all analyses[51].
Results
A total of 272 IDU identified as Aboriginal. An additional
6 that identified as transgendered were excluded from the
analyses due to small numbers, leaving a total sample size
of 266. Overall, 44 (16.5%) of the study sample reported
solvent use in the last 6 months. Table 1 displays a com-
parison of characteristics of solvent and non solvent-
using IDU. Broadly speaking, the two groups differed sig-
nificantly, at least at the p < .05 level, by age, injection
locations, injection risk behaviours, type of drugs
injected and BBP status (Table 1).
Socio-demographic, injection-related and BBP status 
characteristics
Specifically, solvent-using IDU tended to be younger in
age (p < .001) with an average age of 31.6 years (SD: 7.5),
compared to non-solvent-using IDU, who averaged 36.3
years of age (SD: 9.1). Solvent users were more likely to
have reported injecting in a family house (OR: 2.71;
95%CI: 1.32,5.79), empty house (OR: 2.67; 95%CI:
1.16,6.14), hotel (OR: 2.34; 95%CI: 1.20,4.57), shooting
gallery (OR: 2.76; 95%CI: 1.35,5.66) and on the street
(OR: 2.05; 95%CI: 1.05,4.02). Solvent users were more
likely to have reported sharing needles in the last 6
months (OR: 3.74; 95%CI: 1.78,7.85). In terms of the most
frequent drugs injected, solvent users were more likely to
report Talwin & Ritalin injection (OR: 11.69; 95%CI:
4.73,28.87), while less likely to report cocaine (OR: 0.42;
95%CI: 0.22,0.81) and crack (OR: 0.26; 95%CI: 0.09,0.77)
injection. No solvent users reported heroin, amphet-
amines or methadone as their most frequently injected
drug. Finally, solvent users were more likely to be HCV
positive (OR: 3.33; 95%CI: 1.46,7.58). Solvent users were
more likely to be HIV positive than their non-solvent
using counterparts (17.5% versus 8.3%), but this was not
statistically significant at the p < .05 level (p = .076).
Multivariable analysis
After backwards elimination, the following variables
remained in the final logistic regression model (Table 2):
HCV status (p = .016), sharing needles in the last 6
months (p = .048), Talwin & Ritalin injection (p < .001)
and age (p < .001), adjusted for sex. All variables
remained significant if sex was removed from the model.
Discussion
This study examined the association between solvent use
in Aboriginal IDU and socio-demographic factors, drug-
related risk factors, use of other illicit substances and BBP
infection. We found that after adjusting for other vari-
ables including sex, solvent use was significantly associ-
ated with Talwin & Ritalin injection, HCV status and age
in this population.
Some important limitations of the study should be
stated at the outset. First and foremost, ours was a cross-
sectional study, and a causal linkage between solvent use
and injection drug use cannot be inferred from the data.
Although both likely share determinants, our data are
insufficient to establish causality. Aboriginal individuals
in Canada face a combination of socially and structurally
determined vulnerabilities, including high rates of
entrenched poverty, unemployment, homelessness and
sexual and physical abuse[2,52,53]. Many of these factors
stem from a history of colonization, oppression, systemic
racism and discrimination in Canadian society and have
resulted in Aboriginal Canadians having unequal access
to a variety of resources [2,54]. Thus, the perniciousness
of both solvent and injection drug use within Aboriginal
populations is more likely a result of these determinants.
Second, solvent use was measured broadly. The measure
used was not precise enough to discriminate between
chronic and casual use. Similarly, different types of sol-
vents were not captured in this study. Third, since a sam-
pling frame was not possible to construct for this
marginalized and hidden population, the sample was not
randomly generated and may not be representative of
Aboriginal IDUs in other settings, or in Winnipeg.
Fourth, social desirability bias, or high non-response rate
is always an issue with self-reported data; however, it is
likely that this would have served to underestimate asso-
ciations toward the null. Finally, the sample size was rela-
tively small and thus may have not had power to detect
significant findings.
Previous studies in Winnipeg have reported Talwin &
Ritalin injection as being strongly associated with both
Aboriginal ethnicity[50,55] and high HCV preva-
lence[49]. That HCV infection is three times more likely
in the population of solvent-using Aboriginal IDU, after
controlling for Talwin & Ritalin injection and risky injec-
tion practices, strongly suggests the existence of pockets
of higher risk even amongst an already high-risk subpop-Shaw et al. Harm Reduction Journal 2010, 7:16
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Table 1: Characteristics of 266 Aboriginal IDU by solvent-use status, Winnipeg Manitoba
Solvent use status; no. (%)
Users (n = 44) Non-users (n = 222) Odds Ratio (95% CIs) P
Socio-Demographic
Age
15-29 21(47.7) 51(22.4) Ref <.001
30-39 17(38.6) 86(37.7) 0.48 (0.23,0.99)
40+ 6(13.6) 91(39.9) 0.16 (0.07,0.42)
Mean (SD) 31.6(7.5) 36.3(9.1)
Female 25(56.8) 117(52.7) 1.18 (0.62,2.27) .617
Born outside province 5(11.4) 37(16.7) 0.64 (0.24,1.73) .362
At least grade 12 38(86.4) 169(76.1) 2.35 (0.90,6.15) .135
Injection Locations
Own House 27(61.4) 121(54.5) 1.33 (0.68,2.57) .403
Family House 14(31.8) 32(14.4) 2.71 (1.32,5.79) .005
Friend's House 37(84.1) 158(71.2) 2.14 (0.91,5.05) .077
Empty House 10(22.7) 22(9.9) 2.67 (1.16,6.14) .017
Shelter/Hostel 0(0.0) 6(2.3) n/a .277
Hotel 28(63.6) 95(42.8) 2.34 (1.20,4.57) .011
Shooting Gallery 15(34.1) 35(15.8) 2.76 (1.35,5.66) .004
Street 18(40.9) 56(25.2) 2.05 (1.05,4.02) .034
Injection Risk Behaviours
Share needles (Ever) 25(56.8) 104(46.9) 1.49 (0.78,2.87) .227
Share needles (6 months) 15(34.1) 27(12.2) 3.74 (1.78,7.85) <.001
Share injection equipment 13(29.6) 72(32.4) 0.87 (0.43,1.77) .708
Inject someone as service 9(20.5) 62(28.2) 0.66 (0.29,1.44) .291
Inject someone as favour 19(43.2) 97(44.1) 0.96 (0.50,1.85) .912
Ease of obtaining needles 34(77.3) 188(84.7) 0.61 (0.28,1.36) .227
Drugs Injected
Cocaine 21(47.7) 152(68.5) 0.42 (0.22,0.81) .008
Talwin & Ritalin 38(86.4) 78(35.1) 11.69 (4.73,28.87) <.001
Morphine 7(15.9) 63(28.4) 0.48 (0.20,1.12) .086
Heroin 0(0.0) 18(8.1) n/a --
Amphetamines 0(0.0) 4(1.8) n/a --
Methadone 0(0.0) 9(4.1) n/a --
Crack 4(9.1) 61(27.5) 0.26 (0.09,0.77) .010
Crystal Methamphetamine 1(2.3) 9(4.1) 0.55 (0.07,4.46) .570
Dilaudid 3(6.8) 23(10.4) 0.63 (0.18,2.21) .470
Oxycontin 1(2.3) 6(2.7) 0.84 (0.10,7.13) .871
BBP Status
HIV (n = 233) 7(17.5) 16(8.3) 2.34 (0.90,6.15) .082
Hepatitis C (n = 238) 33(80.5) 109(55.3) 3.33 (1.46,7.58) .004Shaw et al. Harm Reduction Journal 2010, 7:16
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ulation[39,47]. It was also demonstrated that these quali-
tatively distinct 'higher-risk' groups can be distinguished
when both injectable and non-injectable drug use is con-
sidered.
The relatively low prevalence of both HIV and HCV
among IDU in our geographic setting has motivated
researchers to ask what role, if any, public health
responses in Winnipeg may have contributed to lower
prevalence[56]. Both HIV and HCV prevalence in the
subset of solvent-using IDU are relatively higher than
other IDU in our sample; and at 18% and 81% respec-
tively, are in closer alignment with the prevalence
observed in other jurisdictions[57,58]. This dichotomy in
prevalence reinforces the exceptionally high risk faced by
solvent-using IDU, and their real or potential ability to be
missed by what otherwise may be an effective public
health response. This higher-risk group is particularly rel-
evant given the recent attention paid to especially high
rates of HIV in Aboriginal populations in central Can-
ada[11,12], and serve to illustrate that BBP epidemics in
Canada are not homogeneous.
Solvent use is an issue where there are no easily-identi-
fiable solutions[23,24]. Solvent users are at the bottom of
a drug-using hierarchy, in terms of perception by other
substance users and practitioners, and by the sheer vol-
ume of their social and personal challenges[29,39,42,47].
Thus, given the already difficult lifestyle and behavioural
issues related to injection drug use[58,59], a combination
of solvent use and injection drug use within Aboriginal
populations may present considerable, and specific chal-
lenges for treatment[39,47]. For example, although there
is well-established literature on the effectiveness of harm-
reduction efforts such as needle-exchange programs in
curtailing the spread of BBPs[60,61], the constituents of
an equivalent and appropriate harm reduction strategy
for solvent users have not been well articulated in the lit-
erature [24], although practical advice may include using
solvents in groups, and using clean rags or sponges. As
well, outreach efforts to these populations may be unduly
hampered by the considerable stigma attached to chronic
solvent use. Similar to recent Canadian research demon-
strating that IDU who also smoked crack cocaine were at
higher risk of HIV seroconversion[10], perhaps an espe-
cially chaotic lifestyle is contributing to the higher HCV
prevalence in our solvent-using subpopulation.
Understanding outlier populations
As Kuller has suggested that understanding epidemics in
"outlier" populations may have substantial benefits in
unpacking transmission dynamics in more mainstream
populations[62], a deeper examination of this, and similar
subpopulations is warranted. Thus, we submit that
understanding the exogenous factors that contribute to
solvent use in IDU may result in better understanding of
marginalized subpopulations in general, particularly with
respect to understanding the trajectory of use[63]. For
example, it has been recognized that solvent use is typi-
cally a group activity[23,24,26]. The natural consequence
is the tendency to form closed networks[64], in this case
comprised of fellow solvent-using IDU. This may be par-
ticularly true in our study population of Aboriginal IDUs,
since individuals have been shown to form more cohesive
structures according to ethnicity[65]. At the same time,
the near ubiquity and accessibility of sources of solvents
and inhalants is clearly a key contributor to their
abuse[66]. Recent programs that seek to address solvent
use in adolescent Aboriginal Canadians through improv-
ing individual-level coping strategies recognize that with-
out multi-level support structures (e.g. family,
community, environment) in place, individual recovery is
likely to fail[25]. Other researchers have found that strong
peer group sanctions against solvent use, in concert with
messages concerning the dangers of solvent use were pro-
tective against lifetime and current use of solvents[23].
Thus, finding ways to identify and engage with solvent
users and their peers may have application with other
hidden and marginalized populations. Along this line,
some authors have suggested that solvent use may be a
marker for an inherently more challenging type of sub-
stance user[19,45]. Thus, it may be useful to understand
to what extent the actual choice of solvent use is a proxy
for characteristics that distinguish the most marginalized
of subpopulations. Understanding the populations that
become chronic abusers of easy-to-obtain substances
Table 2: Adjusted Odds Ratios, Multivariable Logistic Regression of Predictors of Solvent Use, Aboriginal IDU, Winnipeg 
Manitoba
Odds Ratio (95% CIs) Standard Error p
Hepatitis C 3.52 (1.27,14.68) 1.85 .016
Share needles (last 6 months) 2.61 (1.01,6.78) 1.27 .048
Talwin & Ritalin injection 9.97 (3.77,26.34) 4.94 <.001
Age (per year increase) 0.91 (0.86,0.96) 0.02 <.001
Female 0.80 (0.35,1.81) 0.33 .587Shaw et al. Harm Reduction Journal 2010, 7:16
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(such as solvents) may help to facilitate a more general
understanding of subpopulations that have proven to be
intractable to treatment.
The fact that solvent use clusters around Talwin & Rit-
alin injection suggests two other interesting areas for
future research. First, other authors have demonstrated
the advantages of understanding IDU from a poly-injec-
tion drug use perspective[67]. Here, we have demon-
strated the practicality of examining IDU in their use of
both injection and non-injection drugs. At the treatment
level, this perspective highlights the importance of treat-
ing two or more qualitatively distinct addictions concur-
rently[68,69]. For example, Stenbacka et al. demonstrated
that opiate-injecting IDU undergoing methadone mainte-
nance therapy (MMT) were more likely to relapse if they
had co-occurring alcohol abuse issues[69]. Secondly, the
clustering of solvent and Talwin & Ritalin use suggests
that the use of either is driven, to a certain degree, by
opportunism. Although our data cannot provide a defini-
tive answer, it would be useful to know under what cir-
cumstances IDU resort to inhaling solvents. Assuming
inhalation is their 'fallback' method, and philosophically
similar to MMT, perhaps a reliable supply of other inject-
able or non-injectable drugs would deter this subpopula-
tion of IDU from using solvents, and thus prevent some
of the more serious neurological and cognitive deficits
associated with long-term chronic use[70,71].
Conclusion
In conclusion, although addressing social or peer group
norms has long been advocated as part of an effective
prevention and treatment strategy for IDU, perhaps
structural-level interventions are especially indicated for
solvent-using Aboriginal IDU. At a time when rates of
HIV and other BBPs are escalating in Canadian Aborigi-
nal populations, studies like this one can help inform tar-
geted strategies, as well as motivate harm reduction
research in very marginalized populations. The strong
socially-constructed vulnerabilities of Aboriginal popula-
tions, the illegality of injection drug use, the obduracy of
solvent use to traditional regulation and control, and the
extreme marginalization of solvent users may be interact-
ing to create a 'perfect storm' for those IDU already
infected, and those at high risk for infection to slip
through the cracks in public health systems.
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